🟢 Neumora Therapeutics is trading 10% up in pre-market as catalyst remains unclear

Neumora Therapeutics is trading 9.75% higher at $0.52, with no clear company-specific catalyst identified for the October 19 pre-market move.

• The latest company press-release listings show earlier updates, including NMRA-215 toxicology news, rather than a new October 19 announcement.
• Biotech was down pre-market, so sector performance does not explain the upward move; the cause remains unclear.